Occudo Quantitative Strategies LP Tcr2 Therapeutics Inc. Transaction History

Occudo Quantitative Strategies LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$1.86 - $3.75 $32,497 - $65,520	-17,472 Reduced 34.75%	32,803 $59,000
Q2 2022 Aug 15, 2022	SELL	$2.11 - $2.94 $35,403 - $49,330	-16,779 Reduced 25.02%	50,275 $146,000
Q1 2022 May 16, 2022	SELL	$2.4 - $4.71 $170,152 - $333,924	-70,897 Reduced 51.39%	67,054 $185,000
Q4 2021 Feb 14, 2022	BUY	$4.58 - $8.34 $631,815 - $1.15 Million	137,951 New	137,951 $643,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Occudo Quantitative Strategies LP, based on Form 13F filings with the SEC.

Stay updated on Occudo Quantitative Strategies LP with notifications on news.